biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Consequences of a "no" vote: from IR

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 19, 2023 11:39am

154 Views

Post# 35233304

RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

"This could very well end up a YES vote from the BTI shareholders and a NO from Midatech Pharma PLC shareholders which would put BTI on the lurch. I wonder if this concern is in the minds of BTI management."

Midatech has a drug significantly de-risked and in clinical trials and I believe it has held talks with industry concerning a potential deal the CEO said. The best value was to develop the drug further internally. It looks like Midatech firmly believes in the drug and so does BTI who wants to merge with them. Ladenberg Thalmann, Lind, and Armistice Capital are also willing to bet on Midatech's drug. It you have what you believe is a viable drug in clinical trials, and significantly de-risked the best path can be to develop it on your own. The nature of Biodexa is for BTI and Midatech to be able to develop drugs internally as a therapeutics company. The licensing model is limited in value; especially if you believe in what you have.

Midatech has also created an out for Biodexa in the financing and Midatech's CEO believed he could have put together another financing.

"If the 20-day VWAP prior to Closing is less than $0.90, the Company may terminate the Private Placement without penalty; and" Midatech's news release